1. Home
  2. FOXF vs ZLAB Comparison

FOXF vs ZLAB Comparison

Compare FOXF & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FOXF
  • ZLAB
  • Stock Information
  • Founded
  • FOXF 2007
  • ZLAB 2013
  • Country
  • FOXF United States
  • ZLAB China
  • Employees
  • FOXF N/A
  • ZLAB N/A
  • Industry
  • FOXF Motor Vehicles
  • ZLAB Biotechnology: Pharmaceutical Preparations
  • Sector
  • FOXF Consumer Discretionary
  • ZLAB Health Care
  • Exchange
  • FOXF Nasdaq
  • ZLAB Nasdaq
  • Market Cap
  • FOXF N/A
  • ZLAB 3.6B
  • IPO Year
  • FOXF N/A
  • ZLAB 2017
  • Fundamental
  • Price
  • FOXF $28.98
  • ZLAB $32.54
  • Analyst Decision
  • FOXF Buy
  • ZLAB Buy
  • Analyst Count
  • FOXF 7
  • ZLAB 5
  • Target Price
  • FOXF $36.43
  • ZLAB $54.28
  • AVG Volume (30 Days)
  • FOXF 502.6K
  • ZLAB 781.8K
  • Earning Date
  • FOXF 07-31-2025
  • ZLAB 08-05-2025
  • Dividend Yield
  • FOXF N/A
  • ZLAB N/A
  • EPS Growth
  • FOXF N/A
  • ZLAB N/A
  • EPS
  • FOXF N/A
  • ZLAB N/A
  • Revenue
  • FOXF $1,415,479,000.00
  • ZLAB $418,326,000.00
  • Revenue This Year
  • FOXF $5.17
  • ZLAB $44.07
  • Revenue Next Year
  • FOXF $6.34
  • ZLAB $49.13
  • P/E Ratio
  • FOXF N/A
  • ZLAB N/A
  • Revenue Growth
  • FOXF 1.26
  • ZLAB 43.72
  • 52 Week Low
  • FOXF $17.95
  • ZLAB $16.01
  • 52 Week High
  • FOXF $54.86
  • ZLAB $44.34
  • Technical
  • Relative Strength Index (RSI)
  • FOXF 68.06
  • ZLAB 40.19
  • Support Level
  • FOXF $27.55
  • ZLAB $34.26
  • Resistance Level
  • FOXF $29.56
  • ZLAB $35.72
  • Average True Range (ATR)
  • FOXF 1.18
  • ZLAB 1.12
  • MACD
  • FOXF 0.24
  • ZLAB -0.54
  • Stochastic Oscillator
  • FOXF 89.69
  • ZLAB 3.83

About ZLAB Zai Lab Limited

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.

Share on Social Networks: